📊 IRWD Key Takeaways
Is IRWD a Good Investment? Thesis Analysis
Ironwood demonstrates strong operational profitability with a 33.3% operating margin and robust free cash flow generation of $127M, supported by a solid interest coverage ratio of 13.6x. However, the company faces significant balance sheet challenges with negative stockholders' equity of -$261.8M and declining revenue (-15.7% YoY), creating uncertainty about long-term financial sustainability despite near-term cash generation capability.
Why Buy IRWD? Key Strengths
- Exceptional free cash flow generation at 42.9% FCF margin, providing financial flexibility
- Strong operating margins at 33.3% demonstrating operational efficiency in core business
- Healthy interest coverage ratio of 13.6x indicating current debt servicing capacity
- Substantial cash position of $215.5M relative to near-term obligations
IRWD Investment Risks to Consider
- Critical balance sheet deterioration with negative stockholders' equity of -$261.8M indicating potential insolvency or past accumulated losses
- Revenue contraction of -15.7% YoY suggesting declining product demand or market share loss in competitive pharma sector
- High leverage with $199.5M long-term debt against negative equity, limiting financial flexibility and refinancing options
- Minimal capital reinvestment ($34K capex) relative to $296M revenue raises concerns about product pipeline maintenance and future competitiveness
Key Metrics to Watch
- Revenue trend reversal and growth trajectory in subsequent quarters
- Net income sustainability and margin stability amid declining top-line
- Free cash flow maintenance and debt reduction progress
- Stockholders' equity recovery and path to positive book value
- Operating cash flow trends and working capital management
IRWD Financial Metrics
💡 AI Analyst Insight
The 42.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
IRWD Profitability Ratios
IRWD vs Healthcare Sector
How IRONWOOD PHARMACEUTICALS INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IRWD Overvalued or Undervalued?
Based on fundamental analysis, IRONWOOD PHARMACEUTICALS INC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IRWD Balance Sheet & Liquidity
IRWD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: IRONWOOD PHARMACEUTICALS INC's revenue has declined by 18% over the 5-year period, indicating business contraction. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
IRWD Growth Metrics (YoY)
IRWD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $91.6M | -$1.4M | $-0.01 |
| Q2 2025 | $85.2M | -$860.0K | $-0.01 |
| Q1 2025 | $41.1M | -$4.2M | $-0.03 |
| Q3 2024 | $91.6M | -$1.4M | $-0.01 |
| Q2 2024 | $94.4M | -$860.0K | $-0.01 |
| Q1 2024 | $74.9M | -$4.2M | $-0.03 |
| Q3 2023 | $108.6M | $15.3M | $0.09 |
| Q2 2023 | $97.2M | $37.1M | $0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IRWD Capital Allocation
IRWD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for IRONWOOD PHARMACEUTICALS INC (CIK: 0001446847)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRWD
What is the AI rating for IRWD?
IRONWOOD PHARMACEUTICALS INC (IRWD) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRWD's key strengths?
Claude: Exceptional free cash flow generation at 42.9% FCF margin, providing financial flexibility. Strong operating margins at 33.3% demonstrating operational efficiency in core business.
What are the risks of investing in IRWD?
Claude: Critical balance sheet deterioration with negative stockholders' equity of -$261.8M indicating potential insolvency or past accumulated losses. Revenue contraction of -15.7% YoY suggesting declining product demand or market share loss in competitive pharma sector.
What is IRWD's revenue and growth?
IRONWOOD PHARMACEUTICALS INC reported revenue of $296.2M.
Does IRWD pay dividends?
IRONWOOD PHARMACEUTICALS INC does not currently pay dividends.
Where can I find IRWD SEC filings?
Official SEC filings for IRONWOOD PHARMACEUTICALS INC (CIK: 0001446847) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRWD's EPS?
IRONWOOD PHARMACEUTICALS INC has a diluted EPS of $0.15.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRWD a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, IRONWOOD PHARMACEUTICALS INC has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRWD stock overvalued or undervalued?
Valuation metrics for IRWD: ROE of N/A (sector avg: 15%), net margin of 8.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRWD stock in 2026?
Our dual AI analysis gives IRONWOOD PHARMACEUTICALS INC a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRWD's free cash flow?
IRONWOOD PHARMACEUTICALS INC's operating cash flow is $127.0M, with capital expenditures of $34.0K. FCF margin is 42.9%.
How does IRWD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.13 (avg: 2).